



# Resource impact statement

Resource impact

Published: 28 June 2023

[www.nice.org.uk](http://www.nice.org.uk)

NICE has recommended deucravacitinib as an option for treating moderate to severe plaque psoriasis in adults, only if:

- the Psoriasis Area and Severity Index (PASI) is 10 or more and the Dermatology Life Quality Index (DLQI) is more than 10
- the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated
- the company provides deucravacitinib according to the commercial arrangement.

Please see the guidance for further details.

We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 56.6 million people).

This is because the technology is a further treatment option and the overall cost of treatment for this patient group will be similar.

Deucravacitinib has a discount that is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

A resource impact template is provided for completion at a local level. This is because there are now several treatment options (biological and non-biological therapies) including deucravacitinib that are recommended by NICE for plaque psoriasis. Organisations should complete both current and future uptake based on local practice.

This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.